Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Subjects With Moderately to Severely Active Crohn's Disease (UNITI-2)
Brief Summary: This study (UNITI-2) will compare the effects (both positive and negative) of an initial treatment with ustekinumab to a placebo over 8 weeks in patients with moderately to severely active Crohn's disease.


Options:
A: Arm Label: 001; Type: PLACEBO_COMPARATOR; Interventions: Drug: Group 1: Placebo | Arm Label: 002; Type: EXPERIMENTAL; Interventions: Drug: Group 2 ustekinumab 130 mg | Arm Label: 003; Type: EXPERIMENTAL; Interventions: Drug: Group 3: ustekinumab approximately 6 mg/kg | Intervention Type: DRUG; Name: Group 2 ustekinumab 130 mg; Assigned to Arm(s): 002 | Intervention Type: DRUG; Name: Group 3: ustekinumab approximately 6 mg/kg; Assigned to Arm(s): 003 | Intervention Type: DRUG; Name: Group 1: Placebo; Assigned to Arm(s): 001
B: Arm Label: 001; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo SC | Arm Label: 002; Type: EXPERIMENTAL; Interventions: Drug: Ustekinumab 90 mg SC q12w | Arm Label: 003; Type: EXPERIMENTAL; Interventions: Drug: Ustekinumab 90 mg SC q8w | Arm Label: 004; Type: EXPERIMENTAL; Interventions: Drug: Placebo IV, Drug: Ustekinumab 90 mg SC q8w | Arm Label: 005; Type: EXPERIMENTAL; Interventions: Drug: Placebo SC, Drug: Ustekinumab 130 mg IV, Drug: Ustekinumab 90 mg SC q12w | Arm Label: 006; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo SC | Intervention Type: DRUG; Name: Placebo SC; Assigned to Arm(s): 001, 005, 006 | Intervention Type: DRUG; Name: Placebo IV; Assigned to Arm(s): 004 | Intervention Type: DRUG; Name: Ustekinumab 90 mg SC q8w; Assigned to Arm(s): 003, 004 | Intervention Type: DRUG; Name: Ustekinumab 130 mg IV; Assigned to Arm(s): 005 | Intervention Type: DRUG; Name: Ustekinumab 90 mg SC q12w; Assigned to Arm(s): 002, 005
C: Arm Label: Group I: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo; Ustekinumab (CNTO 1275) 45 or 90 mg | Arm Label: Group II: Ustekinumab 45 mg; Type: EXPERIMENTAL; Interventions: Drug: Ustekinumab (CNTO 1275) 45 mg | Arm Label: Group III: Ustekinumab 90 mg; Type: EXPERIMENTAL; Interventions: Drug: Ustekinumab (CNTO 1275) 90 mg | Intervention Type: DRUG; Name: Placebo; Ustekinumab (CNTO 1275) 45 or 90 mg; Assigned to Arm(s): Group I: Placebo | Intervention Type: DRUG; Name: Ustekinumab (CNTO 1275) 45 mg; Assigned to Arm(s): Group II: Ustekinumab 45 mg | Intervention Type: DRUG; Name: Ustekinumab (CNTO 1275) 90 mg; Assigned to Arm(s): Group III: Ustekinumab 90 mg
D: Arm Label: Placebo IV; Type: PLACEBO_COMPARATOR; Interventions: Drug: Group 1: Placebo | Arm Label: Ustekinumab 130 milligram (mg); Type: EXPERIMENTAL; Interventions: Drug: Group 2 ustekinumab 130 mg | Arm Label: Ustekinumab approximately (~) 6 milligram per kilogram (mg/kg); Type: EXPERIMENTAL; Interventions: Drug: Group 3: ustekinumab approximately 6 mg/kg | Intervention Type: DRUG; Name: Group 1: Placebo; Assigned to Arm(s): Placebo IV | Intervention Type: DRUG; Name: Group 2 ustekinumab 130 mg; Assigned to Arm(s): Ustekinumab 130 milligram (mg) | Intervention Type: DRUG; Name: Group 3: ustekinumab approximately 6 mg/kg; Assigned to Arm(s): Ustekinumab approximately (~) 6 milligram per kilogram (mg/kg)

Answer: D